Why did LINCOLN.NS stock spike on 13 Feb 2026?

LINCOLN.NS stock rose after a 12 Feb 2026 earnings update and heavy buying. Key triggers were strong EPS metrics (EPS **INR 39.93**) and volume of **738,475**, which pushed price to **INR 654.30** on NSE.

What is Meyka AI’s price forecast for LINCOLN.NS stock?

Meyka AI's 12‑month forecast for LINCOLN.NS stock is **INR 737.56**, implying a **12.72%** upside from **INR 654.30**. Forecasts are model‑based projections and not guarantees.

How is Lincoln Pharmaceuticals valued versus peers?

Lincoln trades at PE **15.42** and PB **1.72**, below the healthcare sector PE **39.20**, offering relative valuation support. Cash per share is **INR 115.82**, signalling balance sheet strength.

What risks should investors monitor for LINCOLN.NS stock?

Key risks include a long DSO of **122.48** days, cash conversion cycle **113.98** days, margin pressure from input costs, and regulatory or product‑mix shifts that can affect revenues.

What is the Meyka AI grade for LINCOLN.NS stock?

Meyka AI assigns LINCOLN.NS a score of **77.70/100** (Grade **B+**, Suggestion: **BUY**). This factors benchmark, sector, financial growth, metrics, forecasts, and analyst signals.

IN Stocks

LINCOLN.NS Lincoln Pharmaceuticals (NSE): +23.72% to INR 654.30 on 13 Feb 2026, check outlook

ByDanny Kontos February 13, 2026February 13, 2026

LINCOLN.NS stock led NSE top gainers on 13 Feb 2026, jumping 23.72% to close at INR 654.30. The move followed an earnings update announced 12 Feb 2026 and heavy intraday buying of 738,475 shares. Lincoln Pharmaceuticals Limited (LINCOLN.NS) now trades well above its 50‑day average of INR 477.91 and near its 52‑week high of INR 696.00, putting valuation and near‑term targets into focus.